Bio-Rad Laboratories (BIO.B) vs Establishment Labs (ESTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Establishment Labs (ESTA) has outperformed Bio-Rad Laboratories (BIO.B) over the past year, gaining 53.7% versus a gain of 28.2%. Over five years, ESTA leads with a -19.9% price change compared with -50.5% for BIO.B. Bio-Rad Laboratories is the larger company by market cap ($9.76 billion vs $1.84 billion), about 5.3 times the size, while Establishment Labs is growing revenue faster (+27.1% vs +0.7%).
Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -24.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO.B | ESTA |
|---|---|---|
| Share price | $365.08 | $61.67 |
| Market cap | $9.76B | $1.84B |
| 1-day change | 0.00% | +1.75% |
| YTD return | +17.50% | -15.38% |
| 1-year return | +28.15% | +53.71% |
| 5-year return | -50.54% | -19.91% |
| P/E ratio (TTM) | 46.27 | — |
| EPS (TTM) | $7.89 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | $211.08M |
| Revenue growth (YoY) | +0.65% | +27.14% |
| Net income (latest FY) | $759.90M | $-51.06M |
| Gross margin | 51.87% | 69.32% |
| Operating margin | 1.83% | -18.48% |
| Net margin | 29.42% | -24.19% |
| 52-week high | $365.08 | $97.59 |
| 52-week low | $244.54 | $38.38 |
| Distance from 52-week high | 0.00% | -36.81% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +66.11% |
| Average volume | 4 | 427.13K |
| Shares outstanding | 5.06M | 29.80M |
| Employees | 7,450 | 1,004 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 5.3 times larger than Establishment Labs by market value ($9.76B vs $1.84B).
- ESTA has outperformed BIO.B by 25.6 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -24.2 cents for Establishment Labs.
- Establishment Labs grew revenue faster in its latest fiscal year (+27.14% vs +0.65%).
About Bio-Rad Laboratories
BIO.B stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Healthcare · Medical Devices · 7,450 employees
About Establishment Labs
ESTA stock →Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand.
Healthcare · Medical Devices · 1,004 employees
BIO.B vs ESTA FAQ
Which is bigger, Bio-Rad Laboratories or Establishment Labs?
Bio-Rad Laboratories (BIO.B) is larger, with a market capitalization of $9.76B compared with $1.84B for Establishment Labs (ESTA).
Which stock has performed better over the past year, BIO.B or ESTA?
ESTA returned +53.71% over the past 12 months, compared with +28.15% for BIO.B (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Establishment Labs in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.